MX2019007367A - Ligandos de peptido para enlace a mt1-mmp. - Google Patents

Ligandos de peptido para enlace a mt1-mmp.

Info

Publication number
MX2019007367A
MX2019007367A MX2019007367A MX2019007367A MX2019007367A MX 2019007367 A MX2019007367 A MX 2019007367A MX 2019007367 A MX2019007367 A MX 2019007367A MX 2019007367 A MX2019007367 A MX 2019007367A MX 2019007367 A MX2019007367 A MX 2019007367A
Authority
MX
Mexico
Prior art keywords
alkdap
dap
cysteine
amino acid
polypeptide
Prior art date
Application number
MX2019007367A
Other languages
English (en)
Inventor
Teufel Daniel
Mudd Gemma
Pavan Silvia
Original Assignee
Bicycletx Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB1622142.6A external-priority patent/GB201622142D0/en
Priority claimed from GBGB1713560.9A external-priority patent/GB201713560D0/en
Application filed by Bicycletx Ltd filed Critical Bicycletx Ltd
Publication of MX2019007367A publication Critical patent/MX2019007367A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/05—Dipeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/6415—Toxins or lectins, e.g. clostridial toxins or Pseudomonas exotoxins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/573—Immunoassay; Biospecific binding assay; Materials therefor for enzymes or isoenzymes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Un ligando de péptido específico para MT1-MMP que comprende un polipéptido que comprende dos residuos de ácido diaminopropiónico (Dap) o acido N-alquildiaminopropiónico (N-AlkDap), y un tercer residuo seleccionado de cisteína, Dap o N-AlkDap, separados por al menos dos secuencias de bucle, y un andamiaje molecular, el péptido se liga al andamiaje por ligaciones de alquilamino covalentes con los residuos de Dap o N-AlkDap del polipéptido y por ligaciones de tioéter covalentes con la cisteína cuando el tercer residuo es cisteína, tal que dos bucles de polipéptido se forman en el andamiaje molecular, en donde el ligando de péptido comprende una secuencia de aminoácidos de la fórmula (II): -A1-X1-U/O2-X3- X4-G5-A2-E6-D7-F8-Y9-X10-X11-A3- (SEQ ID NO: 1) (II) o una sal farmacéuticamente aceptable de la misma; en donde: A1, A2, y A3 son de manera independiente cisteína, acido L-2,3-diaminopropionico (Dap), ácido N-beta-alquil-L-2,3-diaminopr opionico (N-AlkDap), o ácido N-beta-haloalquil-L-2,3- diaminopropionico (N-HAlkDap), con la condición de que al menos uno de A1, A2, y A3 es Dap, N-AlkDap o N-HAlkDap; X representa cualquiera residuo de aminoácido; U representa un residuo de aminoácido no cargado, polar seleccionado de N, C, Q, M, S y T; y O representa un residuo de aminoácido alifático no polar seleccionado de G, A, I, L, P y V.
MX2019007367A 2016-12-23 2017-12-20 Ligandos de peptido para enlace a mt1-mmp. MX2019007367A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB1622142.6A GB201622142D0 (en) 2016-12-23 2016-12-23 Peptide ligands for binding to MT1-MMP
GBGB1713560.9A GB201713560D0 (en) 2017-08-23 2017-08-23 Peptide ligands for binding to Mt1-Mmp
PCT/EP2017/083954 WO2018115204A1 (en) 2016-12-23 2017-12-20 Peptide ligands for binding to mt1-mmp

Publications (1)

Publication Number Publication Date
MX2019007367A true MX2019007367A (es) 2020-01-27

Family

ID=61094380

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019007367A MX2019007367A (es) 2016-12-23 2017-12-20 Ligandos de peptido para enlace a mt1-mmp.

Country Status (13)

Country Link
US (2) US20190389907A1 (es)
EP (1) EP3559019A1 (es)
JP (1) JP7387440B2 (es)
KR (2) KR20190126294A (es)
CN (1) CN110506049A (es)
AU (1) AU2017383008B2 (es)
BR (1) BR112019012623A2 (es)
CA (1) CA3046156A1 (es)
IL (1) IL267499A (es)
MX (1) MX2019007367A (es)
PH (1) PH12019501667A1 (es)
WO (1) WO2018115204A1 (es)
ZA (1) ZA201903811B (es)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6882978B2 (ja) 2014-10-29 2021-06-02 バイスクルアールディー・リミテッド Ｍｔ１−ｍｍｐに特異的な二環性ペプチドリガンド
GB201607827D0 (en) 2016-05-04 2016-06-15 Bicycle Therapeutics Ltd Bicyclic peptide-toxin conjugates specific for MT1-MMP
WO2018115203A1 (en) 2016-12-23 2018-06-28 Bicyclerd Limited Peptide derivatives having novel linkage structures
US10624968B2 (en) 2017-01-06 2020-04-21 Bicyclerd Limited Compounds for treating cancer
WO2018197893A1 (en) 2017-04-27 2018-11-01 Bicycletx Limited Bicyclic peptide ligands and uses thereof
WO2019002842A1 (en) 2017-06-26 2019-01-03 Bicyclerd Limited BICYCLIC PEPTIDE LIGANDS WITH DETECTABLE FRACTIONS AND USES THEREOF
GB201721265D0 (en) 2017-12-19 2018-01-31 Bicyclerd Ltd Bicyclic peptide ligands specific for EphA2
TWI825046B (zh) 2017-12-19 2023-12-11 英商拜西可泰克斯有限公司 Epha2特用之雙環胜肽配位基
US11180531B2 (en) 2018-06-22 2021-11-23 Bicycletx Limited Bicyclic peptide ligands specific for Nectin-4
GB201810316D0 (en) 2018-06-22 2018-08-08 Bicyclerd Ltd Peptide ligands for binding to EphA2
KR20210038592A (ko) * 2018-07-23 2021-04-07 더 거버너스 오브 더 유니버시티 오브 알버타 유전자 인코딩된 이환형 펩타이드 라이브러리
WO2020084305A1 (en) 2018-10-23 2020-04-30 Bicycletx Limited Bicyclic peptide ligands and uses thereof
WO2020165600A1 (en) 2019-02-14 2020-08-20 Bicycletx Limited Bicyclic peptide ligand sting conjugates and uses thereof
TW202108165A (zh) 2019-05-10 2021-03-01 英商拜西克爾德有限公司 治療癌症之方法
TW202118770A (zh) 2019-07-30 2021-05-16 英商拜西可泰克斯有限公司 異質雙環肽複合物
EP4274597A1 (en) 2021-01-11 2023-11-15 BicycleTX Limited Methods for treating cancer
GB202114282D0 (en) 2021-10-06 2021-11-17 Bicyclerd Ltd Bicyclic peptide ligand drug conjugates
WO2023088236A1 (zh) * 2021-11-16 2023-05-25 海思科医药集团股份有限公司 Mt1-mmp的双环肽配体及其缀合物

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1569956B1 (en) * 2002-12-12 2014-02-26 Tel Aviv University Future Technology Development L.P. Glycogen synthase kinase-3 inhibitors
EP1452868A2 (en) 2003-02-27 2004-09-01 Pepscan Systems B.V. Method for selecting a candidate drug compound
PT1844337E (pt) 2005-01-24 2014-04-03 Pepscan Systems Bv Compostos ligantes, compostos imunogénicos e peptidomiméticos
EP2653543A1 (en) * 2008-02-05 2013-10-23 Bicycle Therapeutics Limited Methods and Compositions
MX2010009530A (es) * 2008-02-27 2010-11-30 Yeda Res & Dev Conjugados de rgd-(bacterio) clorofila para terapia fotodinámica y formación de imágenes de tumores necróticos.
US8293714B2 (en) * 2008-05-05 2012-10-23 Covx Technology Ireland, Ltd. Anti-angiogenic compounds
GB0914110D0 (en) 2009-08-12 2009-09-16 Medical Res Council Peptide libraries
SG11201400888TA (en) * 2011-10-07 2014-04-28 Bicycle Therapeutics Ltd Modulation of structured polypeptide specificity
WO2014190257A2 (en) * 2013-05-23 2014-11-27 Ohio State Innovation Foundation Chemical synthesis and screening of bicyclic peptide libraries
JP6807831B2 (ja) * 2014-05-21 2021-01-06 エントラーダ セラピューティクス，インコーポレイテッド 細胞膜透過性ペプチド、並びにこの作製方法及び使用方法
JP6882978B2 (ja) 2014-10-29 2021-06-02 バイスクルアールディー・リミテッド Ｍｔ１−ｍｍｐに特異的な二環性ペプチドリガンド

Also Published As

Publication number Publication date
CA3046156A1 (en) 2018-06-28
WO2018115204A1 (en) 2018-06-28
US20230340020A1 (en) 2023-10-26
KR20190126294A (ko) 2019-11-11
BR112019012623A2 (pt) 2019-11-19
KR20230042153A (ko) 2023-03-27
ZA201903811B (en) 2020-12-23
AU2017383008B2 (en) 2022-02-17
AU2017383008A1 (en) 2019-06-27
EP3559019A1 (en) 2019-10-30
CN110506049A (zh) 2019-11-26
PH12019501667A1 (en) 2020-02-24
IL267499A (en) 2019-08-29
JP2020514403A (ja) 2020-05-21
JP7387440B2 (ja) 2023-11-28
US20190389907A1 (en) 2019-12-26

Similar Documents

Publication Publication Date Title
MX2019007367A (es) Ligandos de peptido para enlace a mt1-mmp.
HRP20210809T1 (hr) Biciklični peptidni ligandi specifični za mt1-mmp
JP2014224126A5 (es)
MX2009010965A (es) Péptidos de tem8 y vacunas que los contienen.
WO2007056362A3 (en) Glucagon analogs exhibiting physiological solubility and stability
MX2022005483A (es) Composiciones y uso de las mismas para tratar la enfermedad celiaca.
NZ630484A (en) Compositions and methods for treatment of metabolic disorders and diseases
DK2162462T3 (da) Cxc-chemokin-receptor-4 (cxcr4) antagonistisk polypeptid
RU2015146614A (ru) Конъюгированная вакцина на основе пептида антигена wt1
ES2545457T3 (es) Vacunas de péptidos para cánceres que expresan los polipéptidos DEPDC1
MX2020010806A (es) Peptidos anti-inflamatorios y usos de los mismos.
JP2018521983A5 (es)
PL415888A1 (pl) Sposób wytwarzania insuliny i jej pochodnych oraz peptyd hybrydowy stosowany w tym sposobie
RU2015103816A (ru) ПРОНИКАЮЩИЕ В КЛЕТКУ ПЕПТИДЫ, МИШЕНЬЮ КОТОРЫХ ЯВЛЯЕТСЯ eIF4E
WO2005068632A8 (ja) ＨＬＡ−Ａ２４０２拘束性Ｅｐ−ＣＡＭ特異的ＣＴＬが認識するエピトープ・ペプチド及びその用途
MX2020013158A (es) Proteina cas9 modificada y uso de la misma.
MX2020010716A (es) Metodo para escindir de la fase solida peptidos unidos a una fase solida.
NZ586074A (en) LCLRP peptides, constructs and uses thereof
DK2289533T3 (da) Epitoppeptider afledt af karendothelvækstfaktorreceptor-1 samt vacciner indeholdende disse peptider
MX2016011852A (es) Composiciones y metodos para prevenir o tratar la disfuncion cronica del aloinjerto pulmonar (clad) y fibrosis pulmonar idiopatica (fpi).
MX2021001507A (es) Farmaco de diagnostico y metodo de diagnostico para la enfermedad de alzheimer.
EA201991551A1 (ru) Пептидные лиганды для связывания с mt1-mmp
MX2018010682A (es) CICLASA DE TETRAPRENIL-ß-CURCUMENO MUTADA Y METODO PARA PRODUCIR AMBREINA.
MX2018002616A (es) Proteina de fusion.
MX2015002279A (es) Peptido pntx(19) sintético, composición farmacéutica.y uso.